Filing Details

Accession Number:
0001179110-15-016285
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-15 16:34:28
Reporting Period:
2015-12-11
Filing Date:
2015-12-15
Accepted Time:
2015-12-15 16:34:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1157601 Synta Pharmaceuticals Corp SNTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1325712 R Keith Gollust C/O Synta Pharmaceuticals Corp.
45 Hartwell Avenue
Lexington MA 02421
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-12-11 300,000 $0.37 1,839,169 No 4 S Indirect By Wyandanch Partners, L.P.
Common Stock Disposition 2015-12-14 300,000 $0.32 1,539,169 No 4 S Indirect By Wyandanch Partners, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Wyandanch Partners, L.P.
No 4 S Indirect By Wyandanch Partners, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 401,764 Direct
Common Stock 175,000 Indirect By Keith R. Gollust IRA
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $0.35 to $0.3833 per share. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  3. This transaction was executed in multiple trades at prices ranging from $0.2901 to $0.3535 per share. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.